İlmek, Özkan

Profile Picture
Profile URL
https://hdl.handle.net/20.500.12573/2794
Name Variants
İlmek, Özkan
Job Title
Arş. Gör.
Email Address
ozkan.ilmek@agu.edu.tr
Main Affiliation
04.02. Moleküler Biyoloji ve Genetik
Status
Current Staff
Website
ORCID ID
0000-0002-4778-8689
Scopus Author ID
Turkish CoHE Profile ID
318246
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

13

CLIMATE ACTION
CLIMATE ACTION Logo

0

Research Products

17

PARTNERSHIPS FOR THE GOALS
PARTNERSHIPS FOR THE GOALS Logo

0

Research Products

8

DECENT WORK AND ECONOMIC GROWTH
DECENT WORK AND ECONOMIC GROWTH Logo

0

Research Products

9

INDUSTRY, INNOVATION AND INFRASTRUCTURE
INDUSTRY, INNOVATION AND INFRASTRUCTURE Logo

0

Research Products

12

RESPONSIBLE CONSUMPTION AND PRODUCTION
RESPONSIBLE CONSUMPTION AND PRODUCTION Logo

0

Research Products

16

PEACE, JUSTICE AND STRONG INSTITUTIONS
PEACE, JUSTICE AND STRONG INSTITUTIONS Logo

0

Research Products

11

SUSTAINABLE CITIES AND COMMUNITIES
SUSTAINABLE CITIES AND COMMUNITIES Logo

0

Research Products

1

NO POVERTY
NO POVERTY Logo

0

Research Products

6

CLEAN WATER AND SANITATION
CLEAN WATER AND SANITATION Logo

0

Research Products

10

REDUCED INEQUALITIES
REDUCED INEQUALITIES Logo

0

Research Products

14

LIFE BELOW WATER
LIFE BELOW WATER Logo

0

Research Products

15

LIFE ON LAND
LIFE ON LAND Logo

0

Research Products

5

GENDER EQUALITY
GENDER EQUALITY Logo

0

Research Products

4

QUALITY EDUCATION
QUALITY EDUCATION Logo

0

Research Products

7

AFFORDABLE AND CLEAN ENERGY
AFFORDABLE AND CLEAN ENERGY Logo

0

Research Products

3

GOOD HEALTH AND WELL-BEING
GOOD HEALTH AND WELL-BEING Logo

1

Research Products

2

ZERO HUNGER
ZERO HUNGER Logo

0

Research Products
This researcher does not have a Scopus ID.
This researcher does not have a WoS ID.
Scholarly Output

1

Articles

0

Views / Downloads

312/213

Supervised MSc Theses

1

Supervised PhD Theses

0

WoS Citation Count

0

Scopus Citation Count

0

WoS h-index

0

Scopus h-index

0

Patents

0

Projects

0

WoS Citations per Publication

0.00

Scopus Citations per Publication

0.00

Open Access Source

1

Supervised Theses

1

Journals data is not available

Scopus Quartile Distribution

Quartile distribution chart data is not available

Competency Cloud

GCRIS Competency Cloud

Filters

20221
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Master Thesis
    SARS-CoV-2 Omikron Varyantına Özgü Tek Domainli Antikorların Protein-Protein Kenetlenmesi Yaklaşımlarıyla Tanımlanması
    (Abdullah Gül Üniversitesi, Fen Bilimleri Enstitüsü, 2022) İlmek, Özkan; Güner, Şerife Ayaz
    Omicron, became the dominant variant in 2022 in terms of spreading rate, has managed to evade from an immune system of patients due to its unique mutations. Single domain antibodies (sdAb) which are functionally important parts of conventional antibodies are commonly used for diagnosis and treatment. Although there are many sdAbs developed to combat coronavirus in recent years, their effectiveness against Omicron variant has not been sufficiently tested and the effect of mutations regarding neutralization level is not clear. In this study, structure modelling of 850 sdAb sequences obtained from previous studies were generated using AlphaFold 2 and effectiveness of these sdAbs against Omicron variant was tested via protein-protein docking approach. In the docking process, within a realistic approach, missing residues were completed into Spike protein PDB structures, and Spike protein homotrimer structure in closed state conformation was used. Finally, top 1000 and top 100 scores are determined as a threshold value for different protein-protein docking scoring functions such as HDOCK, PRODIGY and Bluues. sdAbs that have successful results for Omicron variant were listed. There were 4 sdAbs which exceed the threshold values after 2 different docking experiments against the Omicron variant. The scripting codes and methodological approach developed within this thesis can be used against new SARS-CoV-2 variants that may emerge in the future or other diseases.